Get the Stockscreener App
1.32
3.13%
0.04
Gri Bio Inc stock is traded at $1.32, with a volume of 279.92K.
It is up +3.13% in the last 24 hours and down -3.65% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.28
Open:
$1.3
24h Volume:
279.92K
Relative Volume:
1.06
Market Cap:
$3.30M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0246
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-33.67%
1M Performance:
-3.65%
6M Performance:
-87.71%
1Y Performance:
-88.75%
1-Day Range:
$1.21
$1.37
1-Week Range:
$1.21
$2.1961
52-Week Range:
$1.10
$30.43
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.32 | 3.20M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
Full technical analysis of GRI Bio Inc. stockLong Term Equity Screener with Safety Metrics - Newser
Why GRI Bio Inc. stock attracts strong analyst attentionAI Pattern Recognition and Trade Prediction - Newser
Using R and stats models for GRI Bio Inc. forecastingFree Risk Adjusted Technical Entry Plan - Newser
Does GRI Bio Inc. show high probability of reboundTrend Following Ideas with Volume Confirmation - Newser
What is the dividend policy of GRI Bio Inc. stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
What are GRI Bio Inc. company’s key revenue driversFree Stock Review For Consistent Profits - jammulinksnews.com
Regression analysis insights on GRI Bio Inc. performanceFree Daily Top Performing Stock Insights - Newser
Is a relief rally coming for GRI Bio Inc. holdersLong-Term Growth Trend Summary With Confidence - Newser
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Plunges 37.62%—What’s Fueling This Sharp Drop in a Biotech Breakthrough? - AInvest
GRI Bio Inc (GRI) Stock: A Comprehensive 52-Week Review - investchronicle.com
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor 'What This Means” Segment - The Manila Times
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewswire Inc.
GRI Bio Announces Pricing of $5.0 Million Public Offering - ADVFN Brasil
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF') - ADVFN Brasil
GRI Bio Announces Closing of $5.0 Million Public Offering - ADVFN Brasil
Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings - Benzinga
GRI Bio reports positive interim biomarker results in IPF treatment study - Investing.com Nigeria
GRI Bio Announces Positive Interim Data for GRI-0621 - TipRanks
GRI Bio's IPF Drug Shows Promising Biomarker Results in Phase 2a Trial: Safety Confirmed - Stock Titan
Humana Lowers 2025 GAAP EPS Guidance - The Globe and Mail
Published on: 2025-07-31 04:48:46 - Newser
Exit strategy if you’re trapped in GRI Bio Inc.Daily Stock Movement Forecast with Accuracy - Newser
Tariff Shocks and Trade Swings: The Real Drivers of U.S. Growth - The Globe and Mail
Global Value: 3 Stocks Under $10 Riding a Weak Dollar - The Globe and Mail
Is GRI Bio Inc. stock poised for growthHistorical Stock Summary and ROI Review - Newser
Comparing Ontrak Inc. in custom built stock radarsFree Quick Gain Stock Watch With Indicators - Newser
Traders Consider Averaging Down in GRI Bio Inc.Proven Entry Plan With Low Risk Shared - metal.it
Is It Too Late to Sell GRI Bio Inc.Low Risk Equity Screener With Results Shared - metal.it
How did GRI Bio's operating expenses trend in Q4 2024 compared to previous quarters? - AInvest
How to track smart money flows in GRI Bio Inc.Near-Term Market Opportunity Forecast Sheet - Newser
Key External Factors That Drive GRI Bio Inc. Stock Price MovementsPredictable Income Summary for Long-Term Trades - Newser
How strong is GRI Bio Inc. company’s balance sheetBest Dividend Data Feed Backed By Experts - jammulinksnews.com
Should I hold or sell GRI Bio Inc. stock in 2025Achieve breakthrough profits with smart strategies - jammulinksnews.com
Does GRI Bio Inc. stock perform well during market downturnsHigh-profit stock alerts - jammulinksnews.com
Why is GRI Bio Inc. stock attracting strong analyst attentionConsistently exceptional gains - jammulinksnews.com
How volatile is GRI Bio Inc. stock compared to the marketBuild wealth faster with high-performing stocks - jammulinksnews.com
How to interpret RSI for GRI Bio Inc. stock Low Risk Stock Selection Strategy Guide - Newser
What is GRI Bio Inc. company’s growth strategySuperior trading gains - jammulinksnews.com
What are the technical indicators suggesting about GRI Bio Inc.Phenomenal investment performance - jammulinksnews.com
How many analysts rate GRI Bio Inc. as a “Buy”Exceptional profit velocity - jammulinksnews.com
What catalysts could drive GRI Bio Inc. stock higher in 2025Get daily updates on promising stocks - jammulinksnews.com
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):